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Thank you very much for submitting your research paper for consideration to The EMBO Journal editorial office. Having received relatively consistent comments from two expert scientists, I am in a position to reach a decision on your study. As you will see, ref#1's report does not add much to the story. However, the very detailed assessment of the second referee pretty much emphasizes both merits but also weaknesses of the study that extends the regulatory role of MO25-kinase to various Ste20 family members. Major criticisms that would need further experimental efforts are indeed complex formation between MO25 and the presumably new targets as well at least some further support for their physiological regulation by MO25. Conditioned on satisfactorily addressing these crucial points, we would be delighted to assess a thoroughly revised paper for eventual publication here.
Please be reminded that it is EMBO Journal policy to allow a single round of revisions only and that the final decision still entirely depends on the content within the last version of your manuscript.
Yours sincerely,
Editor
The EMBO Journal REFEREE REPORTS Referee #1:
Fillipi et al reported that MO25, previously known to bind and regulate STRAD, could bind and regulate other STE20 kinases. Strikingly, OSR1 and SPAK were activated ~100 fold by MO25.
The experiments were well-designed and performed, and the convincing data were presented.
I pointed out only a few minor suggestions. Referee #2:
In this paper the authors have extended their analysis of the function of the MO25 protein, which in complex with the STRADα pseudokinase activates the LKB1 protein kinase through physical interaction within a stable ternary complex. Here, they showed that MO25 also binds to and activates five other protein kinases. They started by noting that several of the residues in the four sites that MO25 contacts in STRADΑin the STRADα/MO25/LKB1 crystal structure are conserved in MST3/4, SPAK,YST1 and OSR1, which are also members of STE20 kinase family, and that three sites are conserved in several others. Kinase assays using GST fusion protein kinases purified from transfected 293 cells and recombinant MO25 showed that out of 26 STE20/STE11/STE7 family kinases tested only the activity of SPAK, OSR1, MST3, MST4 and YSK1 was stimulated. By analyzing interactions between combinations of WT and Site 1 and 2 MO25 mutants with WT and mutant versions these four kinases mutated at the four contact sites, the authors showed that stimulation by MO25 was dependent on the interaction sites in each kinase, and in particular Site 1 in MO25. Next, they used surface plasmon resonance to analyze physical interactions between purified MO25 and purified SPAK, OSR1 and MST4 kinases, compared to MO25/STRADΑinteraction. They found that SPAK, OSR1 and MST4 all bound to MO25 with 5-10 M affinity, as compared to the 50 nM affinity exhibited by STRAD . They went on to show that SPAK and OSR1 phosphorylation of GST fusion proteins of the NKCC1 and NKCC2 kidney ion cotransporter N-terminal cytoplasmic domains in vitro was greatly stimulated by addition of MO25 . Finally, they showed that that siRNA depletion of MO25α and MO25α singly or in combination in HEK293 kidney cells caused a large reduction of the NKCC1 phosphorylation at T203/207/212\ that was induced by hypotonic treatment of the cells.
The authors' discovery that MO25 kinase activating functions can be extended to additional protein kinases in the STE20 family is an interesting advance, and the findings potentially have important consequences for the regulation of NKCC1 and NKCC2 kidney ion cotransporter function by phosphorylation. The evidence that MO25 stimulation of these kinases in vitro is dependent on physical interactions similar to those this group has previously reported for MO25 with the STRADΑpseudokinase is convincing. In my mind, the main issue is whether this function of MO25 is important for the activity of these additional kinases in vivo. The affinity of MST3/4, SPAK,YST1 and OSR1 for MO25 is 100-fold lower than that of STRAD, raising the question of whether complexes between MO25 and these five kinases are in fact formed in vivo, and whether MST3/4, SPAK,YST1 and OSR1 are able to compete effectively with STRADΑfor MO25 in the cell. Although the results of the MO25 siRNA depletion in HEK293 cells support this idea, more needs to be done to show that this is a consequence of a direct interactions between MO25 and OSR1/SPAK of the type that they show stimulates in vitro kinase activity (e.g. by re-expression of mutant forms of MO25 in the depleted cells), and to demonstrate that MO25 complexes with MST3/4, SPAK,YST1 and OSR1 exist in the cell (perhaps through FRET analysis or crosslinking).
1. Apparently, endogenous SPAK1/OSR1/MST3/4 -MO25 complexes cannot be detected by coprecipitation from cells, but it is unclear whether association can be detected by overexpressing both proteins, or whether this might be achieved by depleting STRAD. As indicated above, some evidence that these proteins do interact in the cell would strengthen the paper. 4. Ultimately, it is unclear why this type of regulation evolved. Is the interaction of MO25 with OSR1/SPAK regulated in some way in kidney epithelial cells?
Points: 1. Figure 1 : Since the GST fusion proteins are dimers, the fact that GST-fusion proteins were used as sources of protein kinase in this experiment will have accentuated any stimulatory effect of MO25 through an avidity effect, 2. Figure 3 : The legend and methods do not give the nature and source of the kinase and MO25 preparations used for the SPR preparations. One assumes that the kinase preparations were MBP-or His-tagged recombinant proteins and therefore monomeric. If they were GST fusion proteins, then the affinity measurements will be inaccurate.
3. Figure 5 : The effects of MO25 knockdown on AMPK T172 phosphorylation were not as strong as that on NKCC1 phosphorylation, presumably because STRADΑhas a higher affinity for MO25 than OSR1/SPAK, meaning that residual MO25 in these siRNA treated cells is still sufficient to activate LKB1. We thank the reviewer for their comments and the support for our manuscript. We address the minor points raised by the referee below:
1) What's the difference between MO25α and MO25β? If there is any known functional difference, please mention in Introduction.
Both MO25α and MO25β are able to interact with STRAD and LKB1. Previous work from our laboratory as well as others has shown that MO25α and MO25β activate the LKB1 kinase at the same level (Boudeau et al., and Baas et al. 2003) . We now mention this in our introduction. We have also extended our studies to show both MO25α and MO25β similarly activate SPAK and OSR1 and this new data is now presented in Fig S5 . We agree that the p-3P nomenclature is confusing and have now changed this to pNKCC1 to denote that this represents a previously characterised phospho NKCC1 antibody that recognises NKCC1 phosphorylated at the three residues (Thr203, Thr207 and Thr212) phosphorylated by SPAK/OSR1. We now define this in the legends of Fig 5 and 
The authors' discovery that MO25 kinase activating functions can be extended to additional protein kinases in the STE20 family is an interesting advance, and the findings potentially have important consequences for the regulation of NKCC1 and NKCC2 kidney ion cotransporter function by phosphorylation. The evidence that MO25 stimulation of these kinases in vitro is dependent on physical interactions similar to those this group has previously reported for MO25 with the STRADα; pseudokinase is convincing. In my mind, the main issue is whether this function of MO25 is important for the activity of these additional kinases in vivo. The affinity of MST3/4, SPAK,YST1 and OSR1 for MO25 is 100-fold lower than that of STRAD, raising the question of whether complexes between MO25 and these five kinases are in fact formed in vivo, and whether MST3/4, SPAK,YST1 and OSR1 are able to compete effectively with STRADα; for MO25 in the cell. Although the results of the MO25 siRNA depletion in HEK293 cells support this idea, more needs to be done to show that this is a consequence of a direct interactions between MO25 and OSR1/SPAK of the type that they show stimulates in vitro kinase activity (e.g. by re-expression of mutant forms of MO25 in the depleted cells), and to demonstrate that MO25 complexes with MST3/4, SPAK,YST1 and OSR1 exist in the cell.
We thank the reviewer for the constructive comments. We agree with the reviewer that support for MO25-dependant activation of STE20 kinases in vivo is of great importance, and we have addressed this major point. We have undertaken additional experiments that are now presented in a new Fig 5. We show that re-expression of MO25α in MO25α-siRNA depleted cells restores phosphorylation of endogenous NKCC1 to similar levels observed in control cells. We have also undertaken further experimentation now shown in Fig 5B to study the dependence of endogenous NKCC1 activity (assessed by monitoring uptake of bumetanide sensitive radioactive 86 Rb + into cells) on MO25α expression. We show that knock-down of endogenous MO25α substantially reduces both the basal and stimulated NKCC1 activity in cells.
Below, we outline our response to the reviewer's additional points:
Apparently, endogenous SPAK1/OSR1/MST3/4 -MO25 complexes cannot be detected by coprecipitation from cells, but it is unclear whether association can be detected by overexpressing both proteins, or whether this might be achieved by depleting STRAD. As indicated above, some evidence that these proteins do interact in the cell would strengthen the paper.
As requested we have undertaken additional work to verify whether co-immunoprecipitation of overexpressed MO25α and MST3, MST4 and YSK1 could be detected in HEK293 cells. The data for these experiments is now shown in Fig S13 and demonstrate that MYC-MO25α coimmunoprecipitated with Flag tagged SPAK, MST4 and YSK1. These interactions are likely to be specific, as point mutations of Site-1 and Site-2 on MO25α inhibit MO25-STE20 kinase interaction.
These new data are referred to in the Discussion and Figure S13 of our paper.
What is the relative abundance and concentration of total MO25α/β; in cells compared to those of STRADα, SPAK/OSR1, MST3/4 and YSK1, and, if STRAD is depleted from cells, how much MO25 is left. In other words, is the abundance of free MO25 sufficient to activate the other potential kinase targets?
We agree with the reviewer that the relative abundance is likely to play an important role in regulation of MO25 activation of STRAD and STE20 kinases. We have also compared the expression of MO25α, MO25β and STRADα in a variety of mouse tissues and these data are shown in Figure S14 . These data show that STRADα expression is more variable within tissues than MO25α or MO25β. For example, in kidney tissues, where the SPAK/OSR1-dependent activation of the ion co-transporters is fundamental for regulating blood pressure, STRADα is almost absent, while both MO25α and MO25β are highly expressed. We have added a new paragraph in the discussion to highlight this point. We also discuss previous work demonstrating that in LKB1 knock-out cells, STRAD isoforms are drastically reduced as these are presumably destabilised, whilst levels of MO25α remain unaffected (Hawley et al, 2003) . This also emphasises that MO25 is likely to have roles beyond regulating STRAD and LKB1. We also refer to several elegant genetic studies undertaken in yeast, that strongly indicate that in this species, MO25 functions to regulate STE20 kinases homologous to MST3/MST4 and YSK1 rather than LKB1 orthologues. We also bring up the point that future work will need to address how expression of STE20 kinases and MO25 isoforms is coordinated and how different complex assemblies are controlled in vivo. Our mutagenesis data studying the effects of altering Site-1 and Site-2 on MO25 isoforms or mutating Site-A, Site-B, Site-C and Site-D on MST3/MST4/YSK1 and SPAK/OSR1 (FIG 2B-F,  FIG S3-5 ) strongly suggest that STE20 kinases bind MO25 isoforms in an analogous manner to STRAD. To address this important point raised by the Reviewer, we have added the following paragraph to the Discussion section: "In the MO25α-STRADα complex, STRADα attains an active conformation and the substrate-binding site of STRADα is fully accessible and freely available to bind LKB1 as a pseudosubstrate (Zeqiraj et al, 2009a) . Assuming that the mode of interaction and the mechanism of activation of MO25 and STE20 kinases are similar, the substrate binding site of STE20 kinases should be accessible to their substrates even when these kinases are bound to MO25. In this manner, MO25 isoforms would not need to dissociate from the STE20 kinase in order for these enzymes to access their substrates"
As the authors
We have also emphasised in the Discussion that crystallographic studies of MO25 complexed to STE20 kinases would be very valuable in further assessing the molecular mechanism by which these enzymes are regulated by MO25 isoforms.
Ultimately, it is unclear why this type of regulation evolved. Is the interaction of MO25 with OSR1/SPAK regulated in some way in kidney epithelial cells?
This is an interesting point. In the final paragraph of the discussion we speculate why the ancestral STE20 kinases might have evolved as an ancestral mechanism to activate STE20 kinases. As mentioned above it is difficult to assess the interaction of endogenous MO25 and SPAK/OSR1 due to the micromolar affinity of these proteins for each other. We agree that in future work it would be fascinating to investigate regulatory pathways or additional components might exist to control the assembly of MO25-STE20 kinase complexes and whether there is a specific mechanism in the kidney that regulates formation of SPAK/OSR1-MO25 complexes. It would also be interesting to study whether disruption of these complexes in the kidney could be linked to development of high blood pressure in humans. We have extensively re-written the discussion section of our manuscript in an attempt to bring out this point Points: 1. Figure 1: Since the GST fusion proteins are dimers, the fact that GST-fusion proteins were used as sources of protein kinase in this experiment will have accentuated any stimulatory effect of MO25 through an avidity effect.
Based on this Reviewer's thoughtful comment we have performed additional activity assays with 6-His tagged MST4 purified from insect cells as well as untagged OSR1 purified from bacteria. We found that in the presence of untagged MO25α, the activity of His-MST4 was increased 5-fold and these data are now included in Fig S4G. We also found that the activity of untagged OSR1was stimulated over 70-fold by untagged MO25α and these data are now included in Fig S3E. These effects are similar to what we observed with the GST tagged OSR1 and MST4 fusion proteins presented in Figures 2A, B The OSR1 and SPAK used for the SPR analysis as well as wild type and mutant forms of MO25α were untagged, while MST4 was 6-His tagged. We apologise for the confusion and have now included this information in the figure legend.
3. Figure 5 : The effects of MO25 knockdown on AMPK T172 phosphorylation were not as strong as that on NKCC1 phosphorylation, presumably because STRADα; has a higher affinity for MO25 than OSR1/SPAK, meaning that residual MO25 in these siRNA treated cells is still sufficient to activate LKB1.
The reviewer is right to point out that the effect on T172 of AMPK is not as strong as that on NKCC1. This may be due to compensatory mechanism by another upstream kinase (CAMKK) that is capable of phosphorylating AMPK at T172 (Hawley et al, 2005) . It is also possible that for the LKB1 complex loss of MO25α can be better compensated for by the remaining MO25α and MO25β in the siRNA-treated cells as STRAD isoforms possess higher affinity for MO25 isoforms than SPAK/OSR1.
